First Approved Kinase Inhibitor for AML.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 29149610.
- Also identified by DOI 10.1016/j.cell.2017.11.007.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Activating mutations of FLT3 occur in about 30% of acute myeloid leukemia (AML) cases and are associated with relapse and poor prognosis. Midostaurin is the first drug approved for AML since 2000, and the first multi-kinase inhibitor approved for the FLT3-mutant subtype. To view this Bench to Bedside, open or download the PDF.
Medical subject headings
- Antineoplastic Agents
- Drug Approval
- Leukemia, Myeloid, Acute
- Staurosporine